Advances in diabetes therapy have resulted in the availability to fixed-ratio insulin combinations to help people with diabetes optimize their glycemic control. Familiarizing clinicians and payers with these therapies, their place in the overall management of diabetes, and the patients most likely to benefit from them, will help to support an overall cost-effective approach to diabetes care.
This program reviews the use of fixed combination insulin products to facilitate improved glycemic control through drug therapy and the potential for improved health and economic outcomes resulting from optimized glycemic control diabetic patients.
This program has received an educational grant or in-kind support from Novo Nordisk.